A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VX-708 in healthy participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated

Criteria

Key Inclusion Criteria:

• Male and female of non-childbearing potential are eligible

• Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m^2)

• A total body weight greater than (>) 50 kg

Key Exclusion Criteria:

• History of febrile illness or other acute illness within 14 days before the first dose of study drug

• Any condition possibly affecting drug absorption, distribution, metabolism, or excretion

• History of cardiac dysrhythmias

Other protocol defined Inclusion/Exclusion criteria may apply.